SynthesisMedicine2026
Efficacy and safety of Wenxin Keli for ventricular premature beat: An overview of systematic reviews and meta-analyses.
Synthesis in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWenxin Keli (WXKL) is a common medication used to treat ventricular premature beat (VPB). As a complementary alternative therapy, the clinical efficacy and safety of WXKL-assisted treatment of VPB has been reported by several systematic reviews (SRs), but the quality of evidence has not been systematically reviewed.
methodsWe conducted a literature search on 7 databases until May 1, 2025. Risk of bias in systematic was used to assess the risk of bias in SRs. A measurement tool to Assess Systematic Reviews 2 was used to evaluate the methodological quality of the SRs, respectively. Grading of recommendations assessment, development and evaluation (GRADE) was used to evaluate the quality grading of outcomes.
resultsEleven SRs, including 211 clinical randomized controlled trials and 19,673 patients, met the inclusion criteria. Four SRs (36.36%) were rated as low risk and 7 SRs (63.64%) were rated as high risk. Only 3 SRs had low methodological quality, while the remaining 8 SRs had critically low methodological quality. We evaluated 46 outcomes, with moderate quality evidence in 6 (13.04%), low-quality evidence in 24 (52.17%), very low-quality evidence in 16 (34.78%). The pooled results suggest that WXKL appears to have an advantage in improving 24-hour Holter electrocardiogram and clinical symptoms in VPB, but the overall efficacy in VPB should be interpreted with caution. Meta-analysis showed that WXKL combined with conventional western medications improved the total effective rate (Relative risk [RR] = 1.08, 95% confidence interval [CI]: 1.06-1.11, P < .00001), the effect of 24-hour Holter electrocardiogram (RR = 1.22, 95% CI: 1.17-1.27, P < .00001) and clinical symptoms (RR = 3.00, 95% CI: 2.17-4.27, P < .00001). There were no significant differences in adverse effects (RR = 0.85, 95% CI: 0.68-1.06, P = .16).
conclusionWXKL adjuvant therapy of VPB may be effective, but the evidence quality is low. Physicians should choose carefully in the context of the clinical situation when referring to SRs of WXKL for the treatment of VPB for clinical decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.